Phase 1 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of CBT-101 in Subjects With Advanced Solid Tumors and c-Met Dysregulation
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Jul 2017
At a glance
- Drugs CBT 101-Carlbiotech (Primary)
- Indications Gastric cancer; Oesophageal cancer; Renal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors CBT Pharmaceuticals
- 18 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Jul 2017.
- 01 Jun 2017 Status changed from planning to not yet recruiting.
- 04 Apr 2017 According to a CBT Pharmaceuticals media release, company plan to submit an Investigational New Drug Application soon.